Ataraxis AI

Big day: Ataraxis raised a $20.4 million Series A from @aixventureshq, @peterthiel, and other top tier VC funds and angel investors, including OpenAI & DeepMind researchers.

This funding round comes just a few months after we revealed Ataraxis Breast, the world's first AI-native platform to personalize treatment in breast cancer patients. We also launched Kestrel, our state-of-the-art foundation model for digital pathology.

Our frontier AI lab is dedicated to developing and clinically deploying tools that personalize treatment for cancer patients. In October, an 8,000-patient clinical validation study confirmed that Ataraxis Breast accurately identifies high- and low-risk patients, significantly outperforming legacy diagnostic tests. Ataraxis Breast is just the first of many Ataraxis products, and with our Series A financing, we will accelerate their development and deployment to help cancer patients worldwide.

Ataraxis is already back to building, and we’re looking for exceptional people to join us. If you're passionate about AI and medicine and want to be a part of the fastest-growing AI precision medicine company, consider joining our team: jobs.ashbyhq.com/ataraxis-ai

We are sharing this milestone alongside an exclusive TechCrunch feature.

A huge thank you to our employees, investors, patients, and physicians—this journey wouldn’t be possible without you. This is just the beginning.

Today we're announcing results from a clinical study validating Ataraxis Breast in SWOG-8814 trial data. This landmark Phase III trial assessed the benefit of adding chemotherapy to endocrine therapy in postmenopausal women with node-positive, HR+ breast cancer.

Full Study: go.ataraxis.ai/ctx-swog8814

Today Ataraxis is announcing results of two clinical validation studies of our AI model predicting breast cancer response to neoadjuvant therapy:

1. Clinical validation in @wearemedsir-sponsored PHERGain and PHERGain-2 clinical trials (N=689), which evaluated de-escalated chemotherapy regimens in HER2+ breast cancer. In both trials, Ataraxis successfully predicted both pathologic complete response (pCR) and long-term outcomes: go.ataraxis.ai/neo-phergain

2. Real-world validation in 1,412 patients across nine independent cohorts in five countries, outperforming standard biomarkers, such as tumor-infiltrating lymphocytes: go.ataraxis.ai/neo
In addition to clinical validation data, we also announced MORPHEUS, a new component of Ataraxis’s technology. MORPHEUS is a pan-cancer model trained to predict gene expression from an H&E slide, creating a “virtual molecular portrait” of a patient. MORPHEUS is now included in Ataraxis’s base prognostic/predictive models and lets us build more accurate and interpretable AI models, even when outcome data is scarce. Our research team walks through the methodology and key results in this new blog post: ataraxis.ai/biologically-i…

Thank you to our collaborators, including the
@wearemedsir team.

Legacy tools estimate patient risk. Our AI models predict how each patient will respond to their treatment options. Thanks to @NVIDIAHealth for highlighting how Ataraxis is moving cancer care closer to truly personalized medicine.

Read post: blogs.nvidia.com/blog/ai-breast…

Today we're announcing results from a clinical study validating Ataraxis Breast in the Phase III UNIRAD trial data. The study demonstrated that Ataraxis Breast is prognostic and predictive, and can refine risk assessment among patients eligible for adjuvant CDK4/6 inhibitors.

Full Study: go.ataraxis.ai/ctx-unirad